Serious complications and risk of re-operation after Dupuytren’s disease surgery: a population-based cohort study of 121,488 patients in England

Author:

Alser Osaid,Craig Richard S.,Lane Jennifer C. E.,Prats-Uribe Albert,Robinson Danielle E.,Rees Jonathan L.,Prieto-Alhambra Daniel,Furniss DominicORCID

Abstract

AbstractDupuytren’s disease (DD) is a common fibro-proliferative disorder of the palm. We estimated the risk of serious local and systemic complications and re-operation after DD surgery. We queried England’s Hospital Episode Statistics database and included all adult DD patients who were surgically treated. A longitudinal cohort study and self-controlled case series were conducted. Between 1 April 2007 and 31 March 2017, 121,488 adults underwent 158,119 operations for DD. The cumulative incidence of 90-day serious local complications was low at 1.2% (95% CI 1.1–1.2). However, the amputation rate for re-operation by limited fasciectomy following dermofasciectomy was 8%. 90-day systemic complications were also uncommon at 0.78% (95% CI 0.74–0.83), however operations routinely performed under general or regional anaesthesia carried an increased risk of serious systemic complications such as myocardial infarction. Re-operation was lower than previous reports (33.7% for percutaneous needle fasciotomy, 19.5% for limited fasciectomy, and 18.2% for dermofasciectomy). Overall, DD surgery performed in England was safe; however, re-operation by after dermofasciectomy carries a high risk of amputation. Furthermore, whilst serious systemic complications were unusual, the data suggest that high-risk patients should undergo treatment under local anaesthesia. These data will inform better shared decision-making regarding this common condition.

Funder

Royal College of Surgeons of England

Versus Arthritis

Medical Research Council

NIHR Biomedical Research Centre, Oxford University

National Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference22 articles.

1. Soreide, E. et al. Treatment of Dupuytren’s contracture. Bone Joint J.100-B, 1138–1145 (2018).

2. Nice.org.uk. Collagenase clostridium histolyticum for treating Dupuytren’s contracture - Final scope. https://www.nice.org.uk/guidance/ta459/documents/dupuytrens-contracture-collagenase-clostridium-histolyticum-final-scope2 (2013).

3. Ross, D. C. Epidemiology of Dupuytren’s disease. Hand Clin. 15(53–62), vi (1999).

4. Ng, M. et al. A genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis. Am. J. Hum. Genet. 101, 417–427 (2017).

5. Bayat, A. & McGrouther, D. A. Management of Dupuytren’s disease–clear advice for an elusive condition. Ann. R. Coll. Surg. Engl. 88, 3–8 (2006).

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3